相关实验视频
Updated: Jul 6, 2025

20:16
Detecting Anastasis In Vivo by CaspaseTracker Biosensor
Published on: February 1, 2018
9.3K
乳腺癌放射治疗后第二次皮肤黑色素瘤的风险和预后:基于人口的分析分析
Tianxin Luo1, Yani Zhang1, Tianliang Chen1
1School of Public Health, Guangdong Medical University, Dongguan, China.
Biomolecules & biomedicine
|January 10, 2024
概括
乳腺癌的放射治疗增加了患第二种皮肤黑色素瘤的风险,但这些患者的存活率更高. 总体风险仍然是最小的.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 辐射瘤学 辐射瘤学
背景情况:
- 放射治疗 (RT) 是乳腺癌 (BC) 治疗的基石.
- 人们对RT后可能出现二次非BC瘤的发展存在担忧.
- 皮肤黑色素瘤代表了重要的非BC恶性瘤的兴趣.
研究的目的:
- 在接受RT治疗的BC患者中调查第二次皮肤黑色素瘤 (SCM) 的风险.
- 评估BC患者的生存结果,这些患者在RT后发展到SCM.
主要方法:
- 从SEER数据库中利用了1973-2018年间诊断的520977名BC患者的数据.
- 雇佣的精细灰色竞争风险模型用于累积的SCM发病率.
- 用Poisson回归来计算标准化发病率 (SIR) 和相对风险 (RR).
- 通过卡普兰-梅尔分析评估整体生存率 (OS) 和癌症特异性生存率 (CSS).
主要成果:
- 与非RT患者相比,接受RT的BC患者的SCM风险更高 (HR1.40;P<0.001).
- 在接受RT治疗的BC患者中,SCM的发病率高于美国普通人群 (SIR 1.12;P < 0.05).
- 接受RT的SCM患者表现出明显更好的10年生存率 (14.90%对5.94%;P<0.001).
结论:
- 乳腺癌的RT与患上SCM的可能性增加有关.
- 尽管风险较高,但SCM的绝对风险仍然很低.
- 与不接受RT治疗的SCM患者相比,接受RT治疗的SCM患者的生存结果有所改善.
相关概念视频
Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K
Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353

